227 related articles for article (PubMed ID: 19362126)
1. In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.
Kraft JC; Osterhaus GL; Ortiz AN; Garris PA; Johnson MA
Neuroscience; 2009 Jul; 161(3):940-9. PubMed ID: 19362126
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington's disease.
Lee ST; Park JE; Kim DH; Kim S; Im WS; Kang L; Jung SH; Kim MW; Chu K; Kim M
Brain Res; 2008 Feb; 1194():130-7. PubMed ID: 18166168
[TBL] [Abstract][Full Text] [Related]
3. Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid.
El Massioui N; Ouary S; Chéruel F; Hantraye P; Brouillet E
Exp Neurol; 2001 Nov; 172(1):172-81. PubMed ID: 11681849
[TBL] [Abstract][Full Text] [Related]
4. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
Ramaswamy S; McBride JL; Herzog CD; Brandon E; Gasmi M; Bartus RT; Kordower JH
Neurobiol Dis; 2007 May; 26(2):375-84. PubMed ID: 17336076
[TBL] [Abstract][Full Text] [Related]
5. IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats.
Escartin C; Boyer F; Bemelmans AP; Hantraye P; Brouillet E
Neurosci Lett; 2007 Oct; 425(3):167-72. PubMed ID: 17868993
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes.
Rossignol J; Boyer C; Lévèque X; Fink KD; Thinard R; Blanchard F; Dunbar GL; Lescaudron L
Behav Brain Res; 2011 Mar; 217(2):369-78. PubMed ID: 21070819
[TBL] [Abstract][Full Text] [Related]
7. Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease.
Park JE; Lee ST; Im WS; Chu K; Kim M
Neurosci Lett; 2008 Dec; 448(1):143-7. PubMed ID: 18938211
[TBL] [Abstract][Full Text] [Related]
8. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF.
Puerta E; Hervias I; Barros-Miñones L; Jordan J; Ricobaraza A; Cuadrado-Tejedor M; García-Osta A; Aguirre N
Neurobiol Dis; 2010 May; 38(2):237-45. PubMed ID: 20109548
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats.
Tariq M; Khan HA; Elfaki I; Al Deeb S; Al Moutaery K
Brain Res Bull; 2005 Sep; 67(1-2):161-8. PubMed ID: 16140176
[TBL] [Abstract][Full Text] [Related]
10. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.
Pandey M; Borah A; Varghese M; Barman PK; Mohanakumar KP; Usha R
Neurochem Int; 2009 Nov; 55(6):431-7. PubMed ID: 19410615
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease.
Pandey M; Varghese M; Sindhu KM; Sreetama S; Navneet AK; Mohanakumar KP; Usha R
J Neurochem; 2008 Jan; 104(2):420-34. PubMed ID: 17953654
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide.
Kumar P; Kumar A
Behav Brain Res; 2010 Jan; 206(1):38-46. PubMed ID: 19716383
[TBL] [Abstract][Full Text] [Related]
13. 3-nitropropionic acid-induced mitochondrial permeability transition: comparative study of mitochondria from different tissues and brain regions.
Mirandola SR; Melo DR; Saito A; Castilho RF
J Neurosci Res; 2010 Feb; 88(3):630-9. PubMed ID: 19795369
[TBL] [Abstract][Full Text] [Related]
14. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
[TBL] [Abstract][Full Text] [Related]
15. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
Dhir A; Akula KK; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):835-43. PubMed ID: 18234412
[TBL] [Abstract][Full Text] [Related]
16. Whole body hyperthermia reduces oxidative stress in the striatum of rats in an animal model of mitochondrial toxicity with 3-nitropropionic acid.
Medina-Navarro R; Guerrero-Linares I
Int J Hyperthermia; 2009 Jun; 25(4):280-8. PubMed ID: 19440936
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype.
Tadros MG; Khalifa AE; Abdel-Naim AB; Arafa HM
Pharmacol Biochem Behav; 2005 Nov; 82(3):574-82. PubMed ID: 16337998
[TBL] [Abstract][Full Text] [Related]
18. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Keene CD; Rodrigues CM; Eich T; Linehan-Stieers C; Abt A; Kren BT; Steer CJ; Low WC
Exp Neurol; 2001 Oct; 171(2):351-60. PubMed ID: 11573988
[TBL] [Abstract][Full Text] [Related]
19. Prenatal cadmium and ethanol increase amphetamine-evoked dopamine release in rat striatum.
Nowak P; Dabrowska J; Bortel A; Izabela B; Kostrzewa RM; Brus R
Neurotoxicol Teratol; 2006; 28(5):563-72. PubMed ID: 17005368
[TBL] [Abstract][Full Text] [Related]
20. Worsening of Huntington disease phenotype in CB1 receptor knockout mice.
Mievis S; Blum D; Ledent C
Neurobiol Dis; 2011 Jun; 42(3):524-9. PubMed ID: 21406230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
